tiprankstipranks
Trending News
More News >
Adaptimmune Therapeutics (ADAPY)
OTHER OTC:ADAPY
US Market

Adaptimmune Therapeutics (ADAPY) Income Statement

Compare
1,278 Followers

Adaptimmune Therapeutics Income Statement

Last quarter (Q2 2025), Adaptimmune Therapeutics's total revenue was $13.68M, a decrease of -89.33% from the same quarter last year. In Q2, Adaptimmune Therapeutics's net income was $-30.34M. See Adaptimmune Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 24Dec 23Dec 22Dec 21Dec 20
Total Revenue
$ 178.03M$ 60.28M$ 27.15M$ 6.15M$ 3.96M
Gross Profit
$ 177.96M$ 50.42M$ -100.58M$ -104.94M$ -87.61M
Operating Expenses
$ 246.72M$ 188.42M$ 191.11M$ 168.40M$ 137.36M
Depreciation and Amortization
$ 11.23M$ 9.84M$ 6.07M$ 6.57M$ 7.65M
EBITDA
$ -52.66M$ -128.20M$ -155.59M$ -155.68M$ -125.81M
Operating Income
$ -68.76M$ -138.04M$ -163.97M$ -162.25M$ -133.41M
Other Income/Expenses
$ 1.49M$ 25.50M$ -1.29M$ 4.95M$ 3.48M
Pretax Income
$ -67.27M$ -112.53M$ -162.96M$ -157.30M$ -129.93M
Net Income
$ -70.81M$ -113.87M$ -165.46M$ -158.09M$ -130.09M
Per Share Metrics
Basic EPS
$ -0.05$ -0.09$ -0.17$ -0.17$ -0.15
Diluted EPS
$ -0.05$ -0.09$ -0.17$ -0.17$ -0.15
Weighted Average Shares Outstanding
1.51B 1.21B 967.24M 934.83M 854.78M
Weighted Average Shares Outstanding (Diluted)
1.51B 1.21B 967.24M 934.83M 854.78M
Currency in USD

Adaptimmune Therapeutics Earnings and Revenue History